Ultragenyx Pharma (RARE) Misses Q4 EPS by 28c
Ultragenyx Pharma (NASDAQ: RARE) reported Q4 EPS of ($1.42), $0.28 worse than the analyst estimate of ($1.14).
For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.
Ultragenyx Pharma (NASDAQ: RARE) reported Q4 EPS of ($1.42), $0.28 worse than the analyst estimate of ($1.14).
For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.